BR0309825A - Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasma - Google Patents
Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasmaInfo
- Publication number
- BR0309825A BR0309825A BR0309825-7A BR0309825A BR0309825A BR 0309825 A BR0309825 A BR 0309825A BR 0309825 A BR0309825 A BR 0309825A BR 0309825 A BR0309825 A BR 0309825A
- Authority
- BR
- Brazil
- Prior art keywords
- neoplasm
- mammal
- pharmaceutical composition
- reduce pain
- mammal suffering
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 title abstract 2
- 208000035269 cancer or benign tumor Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 244000309459 oncolytic virus Species 0.000 abstract 3
- 230000000202 analgesic effect Effects 0.000 abstract 2
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 241000702263 Reovirus sp. Species 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 238000001794 hormone therapy Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37867502P | 2002-05-09 | 2002-05-09 | |
| US44317703P | 2003-01-29 | 2003-01-29 | |
| PCT/CA2003/000674 WO2003094938A1 (en) | 2002-05-09 | 2003-05-07 | Method for reducing pain using oncolytic viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0309825A true BR0309825A (pt) | 2005-03-01 |
Family
ID=29423642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0309825-7A BR0309825A (pt) | 2002-05-09 | 2003-05-07 | Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasma |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20040091458A1 (enExample) |
| EP (1) | EP1505992B1 (enExample) |
| JP (1) | JP5241059B2 (enExample) |
| AR (1) | AR039986A1 (enExample) |
| AT (1) | ATE404213T1 (enExample) |
| AU (1) | AU2003229431B8 (enExample) |
| BR (1) | BR0309825A (enExample) |
| CA (1) | CA2484398C (enExample) |
| DE (2) | DE03722131T1 (enExample) |
| DK (1) | DK1505992T3 (enExample) |
| ES (1) | ES2239928T3 (enExample) |
| IL (1) | IL164695A (enExample) |
| MX (1) | MXPA04011007A (enExample) |
| NZ (1) | NZ536102A (enExample) |
| PT (1) | PT1505992E (enExample) |
| SI (1) | SI1505992T1 (enExample) |
| TR (1) | TR200501460T3 (enExample) |
| TW (1) | TWI316405B (enExample) |
| WO (1) | WO2003094938A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US10260049B2 (en) | 2005-08-01 | 2019-04-16 | Virocure, Inc. | Attenuated reovirus |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| WO2008144067A1 (en) * | 2007-05-21 | 2008-11-27 | Board Of Regents, University Of Texas System | Methods and compositions for treatment of cancer using oncolytic rsv activity |
| US8450106B2 (en) * | 2007-10-17 | 2013-05-28 | The Ohio State University Research Foundation | Oncolytic virus |
| MX339014B (es) * | 2008-05-27 | 2016-05-09 | Oncolytics Biotech Inc | Modulacion de presion intersticial y suministro y distribucion viral oncolitica. |
| KR20100054358A (ko) * | 2008-11-14 | 2010-05-25 | 김재은 | 스틱 연고 |
| AU2010242748B2 (en) * | 2009-05-01 | 2015-07-23 | Adare Pharmaceuticals, Inc. | Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs |
| EP2383577A1 (en) * | 2010-04-30 | 2011-11-02 | Deutsches Krebsforschungszentrum | Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy |
| CA2990133A1 (en) | 2015-06-19 | 2017-03-09 | Sillajen, Inc. | Compositions and methods for viral embolization |
| AU2017221592A1 (en) | 2016-02-16 | 2018-10-04 | Osaka University | Pharmaceutical composition for use in treating fibrosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| NZ518945A (en) * | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
-
2003
- 2003-05-07 MX MXPA04011007A patent/MXPA04011007A/es active IP Right Grant
- 2003-05-07 DE DE03722131T patent/DE03722131T1/de active Pending
- 2003-05-07 WO PCT/CA2003/000674 patent/WO2003094938A1/en not_active Ceased
- 2003-05-07 BR BR0309825-7A patent/BR0309825A/pt not_active IP Right Cessation
- 2003-05-07 TR TR2005/01460T patent/TR200501460T3/xx unknown
- 2003-05-07 ES ES03722131T patent/ES2239928T3/es not_active Expired - Lifetime
- 2003-05-07 SI SI200331415T patent/SI1505992T1/sl unknown
- 2003-05-07 NZ NZ536102A patent/NZ536102A/en unknown
- 2003-05-07 EP EP03722131A patent/EP1505992B1/en not_active Expired - Lifetime
- 2003-05-07 AU AU2003229431A patent/AU2003229431B8/en not_active Expired
- 2003-05-07 AT AT03722131T patent/ATE404213T1/de not_active IP Right Cessation
- 2003-05-07 CA CA2484398A patent/CA2484398C/en not_active Expired - Lifetime
- 2003-05-07 DK DK03722131T patent/DK1505992T3/da active
- 2003-05-07 JP JP2004503021A patent/JP5241059B2/ja not_active Expired - Lifetime
- 2003-05-07 PT PT03722131T patent/PT1505992E/pt unknown
- 2003-05-07 DE DE60322885T patent/DE60322885D1/de not_active Expired - Lifetime
- 2003-05-07 TW TW092112420A patent/TWI316405B/zh not_active IP Right Cessation
- 2003-05-08 AR ARP030101621A patent/AR039986A1/es unknown
- 2003-05-08 US US10/431,580 patent/US20040091458A1/en not_active Abandoned
-
2004
- 2004-10-19 IL IL164695A patent/IL164695A/en active IP Right Grant
-
2007
- 2007-06-01 US US11/809,714 patent/US20080081032A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1505992A1 (en) | 2005-02-16 |
| NZ536102A (en) | 2008-01-31 |
| CA2484398C (en) | 2014-01-21 |
| DE03722131T1 (de) | 2005-09-15 |
| ATE404213T1 (de) | 2008-08-15 |
| AU2003229431B8 (en) | 2009-07-02 |
| AU2003229431A1 (en) | 2003-11-11 |
| US20040091458A1 (en) | 2004-05-13 |
| EP1505992B1 (en) | 2008-08-13 |
| JP2005526124A (ja) | 2005-09-02 |
| PT1505992E (pt) | 2008-10-06 |
| AR039986A1 (es) | 2005-03-09 |
| WO2003094938A1 (en) | 2003-11-20 |
| DE60322885D1 (de) | 2008-09-25 |
| ES2239928T1 (es) | 2005-10-16 |
| IL164695A0 (en) | 2005-12-18 |
| IL164695A (en) | 2010-12-30 |
| SI1505992T1 (sl) | 2009-02-28 |
| HK1070565A1 (en) | 2005-06-24 |
| TW200402305A (en) | 2004-02-16 |
| JP5241059B2 (ja) | 2013-07-17 |
| CA2484398A1 (en) | 2003-11-20 |
| AU2003229431B2 (en) | 2008-01-17 |
| TWI316405B (en) | 2009-11-01 |
| DK1505992T3 (da) | 2008-10-06 |
| TR200501460T3 (tr) | 2005-06-21 |
| US20080081032A1 (en) | 2008-04-03 |
| ES2239928T3 (es) | 2009-02-16 |
| MXPA04011007A (es) | 2005-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Malaviya | Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story | |
| Acuña‐Castroviejo et al. | Clinical trial to test the efficacy of melatonin in COVID‐19 | |
| BR0309825A (pt) | Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasma | |
| BR9908030A (pt) | Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado | |
| Gómez‐Ramírez et al. | Short‐term perioperative iron in major orthopedic surgery: state of the art | |
| Bekker et al. | Evaluation of preoperative administration of the cyclooxygenase-2 inhibitor rofecoxib for the treatment of postoperative pain after lumbar disc surgery | |
| BR0314943A (pt) | Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes | |
| BR0009647A (pt) | Docetaxel em combinação com rhumab her2 para o tratamento de cânceres | |
| BR0209689A (pt) | Uso de fragmento de hmg como agente anti-inflamatório | |
| BR0306444A (pt) | Uso de anticorpos anti-tnf(alfa) e outra droga | |
| BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
| BRPI0516531A (pt) | imunoterapia de distúrbios auto-imunes | |
| BR9914901A (pt) | Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca | |
| BRPI0415753A (pt) | método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm | |
| AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
| Routray et al. | Comparison of pregabalin with gabapentin as preemptive analgesic in lumbar spine surgery | |
| BR0317573A (pt) | Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos | |
| Aggarwal et al. | Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study | |
| BRPI0408944A (pt) | método para fornecer um benefìcio de redução de esteróide com um inibidor de ciclooxigenase-2 e composições com este | |
| BR112022001395A2 (pt) | Métodos para administrar anticorpos anti-siglec-8 e corticosteroides | |
| BR112023026992A2 (pt) | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer | |
| BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
| Iacovelli et al. | Avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma. The Tide-A phase 2 study | |
| Pourmand et al. | The evolving landscape of acute pain management in the era of the opioid crisis | |
| Syal et al. | “Protective premedication”: a comparative study of acetaminophen, gabapentin and combination of acetaminophen with gabapentin for post-operative analgesia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES. |